{"version":"https://jsonfeed.org/version/1","title":"Choice ClinOps: Cancer and Rare Disease Clinical Trial Operations Solutions - Fractional and Consulting","home_page_url":"https://choiceclinops.com","description":"Choice ClinOps: Cancer and Rare Disease Clinical Trial Operations Solutions - Fractional and Consulting","author":{"name":"Choice ClinOps: Cancer and Rare Disease Clinical Trial Operations Solutions - Fractional and Consulting"},"items":[{"id":"cro-governance-that-works-a-practical-guide-for-sponsors","html_content":"<img src=\"https://img1.wsimg.com/isteam/ip/b47142d0-5b4b-437f-a7bf-868552964a93/Choice-ClinOps-Fractional-Leadership-CRO-Gover.png\"/><p>You outsourced to a CRO to reduce your internal burden. So why does oversight feel like a full-time job you don't have resources for?</p>","url":"https://choiceclinops.com/insights/f/cro-governance-that-works-a-practical-guide-for-sponsors","title":"CRO Governance That Works: A Practical Guide for Sponsors","date_modified":"2026-02-13T15:24:48Z"},{"id":"the-takeda%E2%80%93iambic-ai-deal-is-a-clinops-wake-up-call","html_content":"<img src=\"https://img1.wsimg.com/isteam/ip/b47142d0-5b4b-437f-a7bf-868552964a93/Takeda-Iambic-Choice-ClinOps-Leila-Cupersmith%20.png\"/><p>AI isn’t just accelerating drug discovery. It’s compressing the timeline to IND—and moving the bottleneck straight into clinical trial operations.</p>","url":"https://choiceclinops.com/insights/f/the-takeda%E2%80%93iambic-ai-deal-is-a-clinops-wake-up-call","title":"The Takeda–Iambic AI Deal Is a ClinOps Wake-Up Call","date_modified":"2026-02-11T01:24:15Z"},{"id":"time-toxicity-the-kpi-sponsors-dont-track-until-the-study-break","html_content":"<img src=\"https://img1.wsimg.com/isteam/stock/109400\"/><p>Most oncology and rare-disease sponsors measure enrollment, cycle time, and vendor performance.</p>","url":"https://choiceclinops.com/insights/f/time-toxicity-the-kpi-sponsors-dont-track-until-the-study-break","title":"Time Toxicity-The KPI Sponsors Don't Track Until the Study Breaks","date_modified":"2026-01-15T15:27:58Z"},{"id":"the-26m-mistake-hiding-between-your-clinical-trial-vendors","html_content":"<img src=\"https://img1.wsimg.com/isteam/ip/b47142d0-5b4b-437f-a7bf-868552964a93/blob-ccb59f5.png\"/><p>Captain James commanded the research vessel Prometheus on its most critical voyage yet. Week 3: a junior engineer reported a small leak.</p>","url":"https://choiceclinops.com/insights/f/the-26m-mistake-hiding-between-your-clinical-trial-vendors","title":"The $2.6M Mistake Hiding Between Your Clinical Trial Vendors","date_modified":"2025-12-31T00:49:53Z"},{"id":"how-can-sponsors-build-value-based-care-into-clinical-trials","html_content":"<img src=\"https://img1.wsimg.com/isteam/ip/b47142d0-5b4b-437f-a7bf-868552964a93/Image%2012-16-25%20at%209.41%E2%80%AFAM.jpeg\"/><p>Value-based care (VBC) is often framed as a reimbursement problem. In reality, patients and care teams experience it as an access + execution problem.</p>","url":"https://choiceclinops.com/insights/f/how-can-sponsors-build-value-based-care-into-clinical-trials","title":"How can sponsors build value-based care into clinical trials?","date_modified":"2025-12-17T03:32:39Z"},{"id":"cro-oversight-steps-for-success-in-small-mid-size-oncology-trial","html_content":"<img src=\"https://img1.wsimg.com/isteam/ip/b47142d0-5b4b-437f-a7bf-868552964a93/Choice-ClinOps-FSP-CRO-Overtsight-The%20Executiv.png\"/><p>A VP of Clinical Operations at a 50-person oncology biotech running their second Phase 2 trial recently confided: \"Every metric is green, but I'm working 60-hour weeks just keeping things from falling apart. I can't tell...</p>","url":"https://choiceclinops.com/insights/f/cro-oversight-steps-for-success-in-small-mid-size-oncology-trial","title":"CRO Oversight: Steps for Success in Small-Mid-Size Oncology Trial","date_modified":"2025-12-12T09:50:17Z"},{"id":"behind-the-scenes-operational-gene-therapy-study-rescue","html_content":"<img src=\"https://img1.wsimg.com/isteam/ip/b47142d0-5b4b-437f-a7bf-868552964a93/blob-50edc03.png\"/><p>When a pivotal gene therapy trial falls behind, timelines aren't the only thing at risk. </p>","url":"https://choiceclinops.com/insights/f/behind-the-scenes-operational-gene-therapy-study-rescue","title":"Behind The Scenes: Operational Gene Therapy Study Rescue ","date_modified":"2025-12-04T05:51:27Z"},{"id":"elevidys-boxed-warnings-and-future-dmd-gene-therapy-clinops","html_content":"<img src=\"https://img1.wsimg.com/isteam/ip/b47142d0-5b4b-437f-a7bf-868552964a93/elevidys-duchenne-gene-therapy-clinical-operat.png\"/><p>When a therapy carries both historic hope and a Boxed Warning, clinical trial operations move from “execution” to responsibility. That is exactly where the Duchenne community now stands with delandistrogene moxeparvovec ...</p>","url":"https://choiceclinops.com/insights/f/elevidys-boxed-warnings-and-future-dmd-gene-therapy-clinops","title":"Elevidys, Boxed Warnings, and Future DMD Gene Therapy ClinOps","date_modified":"2025-11-17T17:08:49Z"},{"id":"poll-results-are-in-poor-communication-tops-45%25","html_content":"<img src=\"https://img1.wsimg.com/isteam/ip/b47142d0-5b4b-437f-a7bf-868552964a93/blob-6a16c09.png\"/><p>Two weeks ago, I, Leila Cupersmith, opened a poll on my LinkedIn profile to identify why clinical trial operations and data-management teams misalign.</p>","url":"https://choiceclinops.com/insights/f/poll-results-are-in-poor-communication-tops-45%25","title":"POLL RESULTS ARE IN: Poor Communication Tops 45%","date_modified":"2025-10-24T02:01:09Z"}]}